BLB&B Advisors LLC Sells 70,744 Shares of Zoetis Inc. $ZTS

BLB&B Advisors LLC decreased its position in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 90.3% during the second quarter, according to its most recent filing with the SEC. The firm owned 7,591 shares of the company's stock after selling 70,744 shares during the period. BLB&B Advisors LLC's holdings in Zoetis were worth $545,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the company. Prosperity Bancshares Inc purchased a new stake in shares of Zoetis in the 4th quarter worth about $25,000. Cassaday & Co Wealth Management LLC bought a new position in shares of Zoetis during the first quarter valued at approximately $28,000. Elyxium Wealth LLC bought a new position in shares of Zoetis during the fourth quarter valued at approximately $32,000. Root Financial Partners LLC lifted its holdings in shares of Zoetis by 66.5% during the first quarter. Root Financial Partners LLC now owns 258 shares of the company's stock valued at $30,000 after purchasing an additional 103 shares during the last quarter. Finally, Wellington Grp LLC lifted its holdings in shares of Zoetis by 6,675.0% during the first quarter. Wellington Grp LLC now owns 271 shares of the company's stock valued at $32,000 after purchasing an additional 267 shares during the last quarter. Institutional investors own 92.80% of the company's stock.

Zoetis Stock Performance

Shares of ZTS opened at $73.64 on Friday. The firm has a market capitalization of $30.43 billion, a P/E ratio of 12.13, a PEG ratio of 1.28 and a beta of 0.74. The company has a debt-to-equity ratio of 2.87, a current ratio of 3.08 and a quick ratio of 1.84. Zoetis Inc. has a one year low of $71.45 and a one year high of $160.48. The business has a fifty day moving average of $76.30 and a 200 day moving average of $99.01.

Zoetis (NYSE:ZTS - Get Free Report) last posted its earnings results on Thursday, August 6th. The company reported $1.87 earnings per share for the quarter, beating analysts' consensus estimates of $1.85 by $0.02. The company had revenue of $2.47 billion for the quarter, compared to the consensus estimate of $2.50 billion. Zoetis had a return on equity of 74.89% and a net margin of 27.49%.Zoetis's revenue was down .2% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.76 earnings per share. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. As a group, sell-side analysts anticipate that Zoetis Inc. will post 6.19 EPS for the current year.

Zoetis Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Monday, July 20th will be paid a $0.53 dividend. This represents a $2.12 annualized dividend and a dividend yield of 2.9%. The ex-dividend date is Monday, July 20th. Zoetis's dividend payout ratio is 34.93%.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the company. Argus reissued a "hold" rating on shares of Zoetis in a report on Wednesday, May 27th. Citigroup lowered their target price on shares of Zoetis from $112.00 to $96.00 and set a "buy" rating on the stock in a research note on Tuesday, August 11th. Barclays dropped their price target on shares of Zoetis from $136.00 to $85.00 and set an "equal weight" rating on the stock in a report on Wednesday, July 1st. Weiss Ratings lowered shares of Zoetis from a "sell (d+)" rating to a "sell (d)" rating in a research note on Friday, June 12th. Finally, UBS Group decreased their price objective on shares of Zoetis from $85.00 to $80.00 and set a "neutral" rating for the company in a report on Friday, August 7th. Eight analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus target price of $109.62.

Zoetis Company Profile

Zoetis Inc NYSE: ZTS is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company's offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source